Stockscreener 앱 받기
0.2881
6.70%
0.0181
시간 외 거래:
.29
0.0019
+0.66%
전일 마감가:
$0.27
열려 있는:
$0.27
하루 거래량:
1.51M
Relative Volume:
0.36
시가총액:
$8.01M
수익:
-
순이익/손실:
$-22.71M
주가수익비율:
-0.0246
EPS:
-11.71
순현금흐름:
$-18.24M
1주 성능:
+2.20%
1개월 성능:
+20.04%
6개월 성능:
-73.81%
1년 성능:
-88.19%
1일 변동 폭
$0.2686
$0.30
1주일 범위
$0.215
$0.30
52주 변동 폭
$0.215
$4.0899
Genprex Inc Stock (GNPX) Company Profile
명칭
Genprex Inc
전화
512-537-7997
주소
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
GNPX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.2881 | 6.67M | 0 | -22.71M | -18.24M | -11.71 |
|
ONC
Beigene Ltd Adr
|
236.86 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.18 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2996 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.79 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-01-26 | 개시 | National Securities | Buy |
| 2019-04-29 | 개시 | Noble Capital Markets | Outperform |
Genprex Inc 주식(GNPX)의 최신 뉴스
WestPark Capital Leads Placement for GNPX | GNPX Stock News - GuruFocus
Genprex (GNPX) to Release Quarterly Earnings on Wednesday - Defense World
Things To Consider Before Buying Genprex Inc (NASDAQ: GNPX) - Stocksregister
Genprex and University of Pittsburgh sign new agreement to study GPX-002 for diabetes - BioWorld MedTech
Attention Investors: What’s Really Going On With Genprex Inc (NASDAQ: GNPX) - Stocksregister
Genprex Announces Research Agreement for Diabetes Therapy - TipRanks
Genprex (GNPX) Advances Diabetes Therapy Research with New Agreement | GNPX Stock News - GuruFocus
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes | GNPX Stock News - GuruFocus
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes - Nasdaq
Genprex (GNPX) Secures Exclusive Patent License for Gene Therapy - GuruFocus
Genprex (GNPX) Secures Exclusive Patent License for Gene Therapy | GNPX Stock News - GuruFocus
Genprex Secures Exclusive Patent License for Reqorsa - TipRanks
Genprex Signs Exclusive License to Additional Gene Therapy Techn - GuruFocus
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma | GNPX Stock News - GuruFocus
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma - PR Newswire
Geode Capital Management LLC Grows Position in Genprex, Inc. (NASDAQ:GNPX) - Defense World
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - ADVFN
Genprex Inc (NASDAQ: GNPX) Is The Number One Stock Currently Moving. - Stocksregister
Genprex (GNPX) Showcases Promising Results for Reqorsa Gene Ther - GuruFocus
Genprex Collaborators Report Positive Preclinical Data On The Use Of Reqorsa Gene Therapy - TradingView
Genprex Collaborators Report Positive Preclinical Data on the Us - GuruFocus
Financial Metrics Check: Genprex Inc (GNPX)’s Ratios for Trailing Twelve Months - DWinneX
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting - PR Newswire
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - The Malaysian Reserve
Genprex Collaborators to Present Positive Preclinical Data on Di - GuruFocus
Taking the lead: Genprex Inc (GNPX) - Sete News
Understanding the Risks of Investing in Genprex Inc (GNPX) - knoxdaily.com
Genprex collaborators report positive preclinical data on the use of Reqorsa gene therapy at the 2025 AACR Annual Meeting - Select Science
Genprex (GNPX) Secures Exclusive Patent License for Mesothelioma - GuruFocus
Indo-Asian News Service - Indo-Asian News Service (IANS)
Genprex secures exclusive license for mesothelioma gene therapy By Investing.com - Investing.com South Africa
Genprex secures exclusive license for mesothelioma gene therapy - Investing.com Australia
Choosing between riding the trend or protecting profits: Genprex Inc (GNPX) - uspostnews.com
Genprex Inc (NASDAQ: GNPX) Stock’s Potential for Success in the Coming Months - Marketing Sentinel
Genprex Signs Exclusive Technology License Agreement with New Yo - GuruFocus
Genprex (GNPX) Secures Exclusive License for Gene Therapy Patent - GuruFocus
Genprex Signs Agreement With New York University Langone Health - marketscreener.com
Revolutionary Gene Therapy Shows 84% Target Success in Mesothelioma Treatment: Genprex-NYU Partnership - Stock Titan
Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma - The Malaysian Reserve
Short Interest in Genprex, Inc. (NASDAQ:GNPX) Grows By 487.6% - Defense World
Stock Market Recap: Genprex Inc (GNPX) Concludes at 0.27, a 0.57 Surge/Decline - DWinneX
GNPX’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
Now Is The Time To Build A Position In Genprex Inc (NASDAQ:GNPX) - Marketing Sentinel
Genprex Selected to Present Trial Design of Acclaim-3 Clinical T - GuruFocus
Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Seeking Alpha
Genprex Inc (GNPX) receives a Buy rating from National Securities - knoxdaily.com
Genprex presents promising gene therapy data for lung cancer By Investing.com - Investing.com South Africa
How Are Things Looking For Genprex Inc (NASDAQ: GNPX) For The Short Term? - Stocksregister
Genprex presents promising gene therapy data for lung cancer - Investing.com
Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings - GuruFocus
There is no doubt that Genprex Inc (GNPX) ticks all the boxes. - Sete News
Genprex Inc (GNPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.33%
1.09%
자본화:
|
볼륨(24시간):